Abstract

Based on the strong activity of belinostat, the study synthesized of some cinnamoylhydroxamic acid derivatives with the aim of creating new compounds that have the potential to selectively inhibit HDAC to contribute to cancer treatment. N-hydroxycinnamamide serves as both ZBG and the linker group. The derivatives orient to the HDAC2 and HDAC8 enzymes by molecular docking. Compound 9a (bearing sulfonamide) exhibited as the most potential candidate to inhibit the function of HDAC2 enzyme.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call